Veracyte (VCYT)
(Delayed Data from NSDQ)
$19.31 USD
-0.17 (-0.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $19.30 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.31 USD
-0.17 (-0.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $19.30 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
by Zacks Equity Research
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 42.86% and 2.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Instruments Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth. HOLX, MASI and VCYT appear well-poised to brave the challenges.
The Zacks Analyst Blog Highlights Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath
by Zacks Equity Research
Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath are part of the Zacks top Analyst Blog.
5 Top-Ranked Cathie Wood Stocks to Buy Right Now
by Aniruddha Ganguly
Here, we have picked five Cathie Wood stocks, Palantir (PLTR), Veracyte (VCYT), PagerDuty (PD), Roku (ROKU) and UiPath (PATH), which are well-poised for healthy returns in 2024.
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 25% and 7.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 14.89% and 8.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 23.53% and 17.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 21.43% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 66.67% and 6.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Best Momentum Stocks to Buy for January 24th
by Zacks Equity Research
VIPS, VCYT and EVR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 24, 2023.
Terex and Armstrong World Industries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Terex and Armstrong World Industries are part of the Zacks Bull and Bear of the Day article.
3 Medical Instruments Stocks on Recovery Path After Dismal 2022
by Indrajit Bandyopadhyay
Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.
What Makes Veracyte (VCYT) a New Buy Stock
by Zacks Equity Research
Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 50% and 12.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 38.10% and 8.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 41% Upside in Veracyte (VCYT): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 13.04% and 9.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of -7.14% and 6.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -36.49% and 0.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Q4 Earnings Lag Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Veracyte (VCYT) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 25.29% and 18.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?